Steroids and/or Cytotoxic Agents Should Be Used Early in the Management of Patients with IPF -- The Pro Argument by Sat Sharma

“…However, the natural history and response to therapy differs substantially, as some categories have more favourable prognoses than others (2). Idiopathic pulmonary fibrosis (IPF) or fibrosing alveolitis is the clinical terminology for a specific interstitial pneumonia for which the pathological process is UIP. …”
Get full text

Updates in the management of connective tissue disease-associated interstitial lung disease by Chengappa Kavadichanda, G S R S N K Naidu

“…Most of the evidence in treating these cases is limited to a few trials in scleroderma and idiopathic pulmonary fibrosis along with several observational studies in other CTDs. …”
Get full text

Evaluation of Inflammatory Cytokine Secretion by Human Alveolar Macrophages by J. E. Losa García, F. M. Rodríguez, M. R. Martín de Cabo, M. J. García Salgado, J. P. Losada, L. G. Villarón, A. J. López, J. L. P. Arellano

“…Human AMs were collected by bronchoalveolar lavage (BAL) from four healthy controls and 13 patients with diffuse interstitial lung disease (five cases of sarcoidosis, three of hypersensitivity pneumonitis and five of idiopathic pulmonary fibrosis). AMs were cultured in the presence or absence of different concentrations of lipopolysaccharide (LPS), phorbolmyristate and gammainterferon. …”
Get full text

Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease by Leslie B. Tolle

“…The tyrosine kinase inhibitor nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype, and systemic sclerosis-associated ILD. …”
Get full text

Moving from an “anti-aging” paradigm toward the concept of “disease-free aging”: the role of senolytics in modern medicine by Ivan Aprahamian, Andréia Pain, Virgílio Garcia Moreira

“…Senolytic therapy requires strong evidence in human trials, and dasatinib and quercetin have shown good results in phase II trials with idiopathic pulmonary fibrosis and diabetic renal disease. However, these trials are small and merely represent a proof-of-concept for these drugs. …”
Get full text

Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics by Chang Yi Shi, Chen Huan Yu, Wen Ying Yu, Hua Zhong Ying

“…Patients with chronic respiratory diseases, including asthma, COPD, bronchiectasis, and idiopathic pulmonary fibrosis, often have alteration of the composition and function of intestinal and lung microbiota. …”
Get full text

PLAC8 attenuates pulmonary fibrosis and inhibits apoptosis of alveolar epithelial cells via facilitating autophagy by Wei Sun, Bo Zhao, Zhong He, Lihua Chang, Wei Song, Yingying Chen

“…Abstract Idiopathic pulmonary fibrosis (IPF) is an irreversible lung condition that progresses over time, which ultimately results in respiratory failure and mortality. …”
Get full text

Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea by Ayodeji Adegunsoye, Jay Balachandran

“…Patients with idiopathic pulmonary fibrosis commonly have obstructive sleep apnea, which potentiates the hypoxic stimuli for oxidative stress, culminating in systemic inflammation and generalized vascular endothelial damage. …”
Get full text

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases by Jin-nan Wu, Jian-rong Chen, Jin-liang Chen

“…In recent years, several studies have shown that FXR is widely involved in the pathogenesis of various respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, and idiopathic pulmonary fibrosis. Moreover, a number of works have confirmed that FXR can regulate the bile acid metabolism in the body and exert its anti-inflammatory and antifibrotic effects in the airways and lungs. …”
Get full text

Ginkgolide B Blocks Vascular Remodeling after Vascular Injury via Regulating Tgfβ1/Smad Signaling Pathway by Quan Wang, Shuai Ni, Li Ling, Siqi Wang, Hanbin Xie, Zhanhong Ren

“…Moreover, the beneficial effect of GB is abolished after incubated with pirfenidone (PFD, a drug for idiopathic pulmonary fibrosis, IPF), which can inhibit Tgfβ1. …”
Get full text

Optimized digital workflow for pathologist-grade evaluation in bleomycin-induced pulmonary fibrosis mouse model by Toshiki Goto, Akira Sano, Shinichi Onishi, Natsuko Hada, Rui Kimata, Saori Matsuo, Sohei Oyama, Atsuhiko Kato, Hideaki Mizuno, Masaki Yamazaki

“…Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disorder of unknown etiology, characterized by interstitial fibrosis of the lungs. …”
Get full text

Factors Influencing Oxidative Imbalance in Pulmonary Fibrosis: An Immunohistochemical Study by Simona Inghilleri, Patrizia Morbini, Ilaria Campo, Michele Zorzetto, Tiberio Oggionni, Ernesto Pozzi, Maurizio Luisetti

“…Background. Idiopathic Pulmonary Fibrosis (IPF) is a fatal lung disease of unknown etiology characterized by interstitial fibrosis determining irreversible distortion of pulmonary architecture. …”
Get full text

Picking interstitial lung disease out of the myositis haystack by Jennifer Hannah, Harsha Gunawardena

“…ILD can be the initial presenting feature and this can make recognition of an underlying CTD-IIM overlap more difficult with some patients initially misdiagnosed with idiopathic pulmonary fibrosis. Therefore, early recognition and characterization of patients can influence management and prognosis. …”
Get full text

Reducing M2 macrophage in lung fibrosis by controlling anti-M1 agent by Fatemeh Bahram Yazdroudi, Alaeddin Malek

“…Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by excessive scarring and fibrosis due to the abnormal accumulation of extracellular matrix components, primarily collagen. …”
Get full text

Assessment and follow-up of interstitial lung disease by Devarasetti Phani Kumar

“…Screening guidelines based on expert opinion are available for idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs (sarcoidosis, hypersensitivity pneumonitis, and systemic sclerosis). …”
Get full text

Bleomycin-Treated Chimeric Thy1-Deficient Mice with Thy1-Deficient Myofibroblasts and Thy-Positive Lymphocytes Resolve Inflammation without Affecting the Fibrotic Response by Pazit Y. Cohen, Raphael Breuer, Philip Zisman, Shulamit B. Wallach-Dayan

“…Accumulation of Thy1-negative (Thy1−) myofibroblasts was shown in the lungs of humans with idiopathic pulmonary fibrosis (IPF) and of bleomycin-treated mice. …”
Get full text

Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias by Toru Arai, Tomoko Kagawa, Yumiko Sasaki, Reiko Sugawara, Chikatoshi Sugimoto, Kazunobu Tachibana, Yoshiki Fujita, Seiji Hayashi, Yoshikazu Inoue

“…Hemosiderin-laden macrophages (HLMs) have been identified in the bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF). This retrospective study examined the ability of HLMs in BALF to predict the acute exacerbation (AE) of chronic idiopathic interstitial pneumonias (IIPs). …”
Get full text

Human epididymis protein 4-annexin II binding promotes aberrant epithelial-fibroblast crosstalk in pulmonary fibrosis by Weishuai Zheng, Menglin Zou, Xingxing Hu, Han Gao, Weiwei Song, Qinhui Hou, Yuan Liu, Zhenshun Cheng

“…Abstract Invasive lung myofibroblasts are the main cause of tissue remodeling in idiopathic pulmonary fibrosis (IPF). A key mechanism contributing to this important feature is aberrant crosstalk between the abnormal/injured lung epithelium and pulmonary fibroblasts. …”
Get full text

MAIT cells protect against sterile lung injury by Xiawei Zhang, Shuailin Li, Wojciech Lason, Maria Greco, Paul Klenerman, Timothy S.C. Hinks

“…Human scRNA-seq data revealed that MAIT cells were activated, with increased cDC populations in idiopathic pulmonary fibrosis patients. Thus, MAIT cells enhance defense against sterile lung injury by fostering cDC1-driven anti-fibrotic pathways.…”
Get full text

“Etiology and CT pattern in patients with interstial lung disease”: shift in the trends? by Abhishek Samdesi, Alamelu Haran, Navya Chinnaswamy Narayanaswamy

“…Second most common etiology was Idiopathic Pulmonary Fibrosis (IPF) (n=15, 14.42%). The UIP pattern was observed in 59.32% patients with CTD-ILD (n = 35) and in 100% patients with the IPF. …”
Get full text